Launch Of The First Intra-Nasal Covid-19 Vaccine In India, INCOVACC

Science and Technology Minister Jitendra Singh and Union Health Minister Dr. Mansukh Mandaviya introduced the first nasal vaccination produced in India against Covid-19, the iNCOVACC.

Bharat Biotech has created the vaccine. At Mandaviya's house, the first intranasal vaccine produced in India was introduced to the world.

On January 26, Republic Day, our nasal vaccine will be formally introduced, the company's chairman and managing director Krishna Ella announced while taking part in the IISF's "Face-to-Face with New Frontiers in Science" segment on Saturday at the Maulana Azad National Institute of Technology (MANIT).

Bharat Biotech has previously declared that it will offer the intranasal vaccine for 325 for government purchases and 800 for commercial immunization facilities.

Bharat Biotech recently declared iNCOVACC® (BBV154) to be a booster dosage throughout the nation.

The Central Drugs Standard Control Organization (CDSCO) had earlier this month given Bharat Biotech permission to employ heterologous booster dosages of iNCOVACC.

"iNCOVACC is a pre-fusion-stabilized SARS-CoV-2 spike protein recombinant replication-deficient adenovirus vectored vaccine. Clinical studies for this vaccine candidate were conducted in stages I, II, and III with positive outcomes. Nasal drops can be used to administer iNCOVACC®, which was created expressly to facilitate intranasal administration. The statement added, "The nasal delivery system has been conceived and developed to be affordable in low- and middle-income nations.